According to the IDH condition, gliomas are divided into IDH-mutant (IDH1 R132 or IDH2 R172) and IDH-wild-type; 90% of GBMs (usually primary or “de novo” GBMs) are wild-type for IDH and have a poor prognosis (median OS of 1.2 years). The gene discussed is IDH1; the disease is central nervous system cancer.